46083
document
Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies : a randomised controlled crossover trial . Twenty-two children with autism spectrum disorders who had not responded to supported behaviour management strategies for severe dysomnias entered a double blind , randomised , controlled crossover trial involving 3 months of placebo versus 3 months of melatonin to a maximum dose of 10 mg. 17 children completed the study . There were no significant differences between sleep variables at baseline . Melatonin significantly improved sleep latency ( by an average of 47 min ) and total sleep ( by an average of 52 min ) compared to placebo , but not number of night wakenings . The side effect profile was low and not significantly different between the two arms .
46084
Intervention_Pharmacological
Melatonin
46085
Intervention_Control
placebo
46086
Intervention_Control
placebo
46087
Intervention_Pharmacological
melatonin
46088
Intervention_Pharmacological
Melatonin
46089
Intervention_Control
placebo
46090
Outcome_Physical
sleep variables
46091
Outcome_Physical
improved sleep latency
46092
Outcome_Physical
total sleep
46093
Outcome_Adverse-effects
side effect profile
46094
Participant_Age
children
46095
Participant_Condition
autism spectrum
46096
Participant_Condition
sleep problems
46097
Participant_Sample-size
Twenty-two
46098
Participant_Condition
autism spectrum disorders
46099
Participant_Condition
dysomnias
46100
Participant_Sample-size
17
46101
Participant_Age
children